Brief: Fate Therapeutics Announces Expansion Of Solid Tumor Collaboration With Ono Pharmaceutical For Off-The-Shelf, Ipsc-Derived Car Nk And Car T-Cell Cancer Immunotherapies

Fate Therapeutics

28/06/2022 12:29

June 28 (Reuters) - Fate Therapeutics Inc  FATE.O :
    * FATE THERAPEUTICS ANNOUNCES EXPANSION OF SOLID TUMOR
COLLABORATION WITH ONO PHARMACEUTICAL FOR OFF-THE-SHELF,
IPSC-DERIVED CAR NK AND CAR T-CELL CANCER IMMUNOTHERAPIES
    * FATE THERAPEUTICS INC - EXPANDED PARTNERSHIP ENABLES
DEVELOPMENT
OF BOTH CAR NK AND CAR T-CELL COLLABORATION CANDIDATES FOR SOLID
TUMORS
    * FATE THERAPEUTICS INC - FATE RETAINS ALL RIGHTS OF
MANUFACTURE
OF COLLABORATION PRODUCTS ON A GLOBAL BASIS
    * FATE THERAPEUTICS -UNDER DEAL, CO RETAINS RIGHT TO JOINTLY
DEVELOP, COMMERCIALIZE CAR NK & CAR T-CELL PRODUCT CANDIDATES IN
U.S.,  EUROPE

Source text for Eikon:  ID:nGNX5WzvW1 
Further company coverage:  FATE.O 

 ((Reuters.Briefs@thomsonreuters.com;))